Is Sab Biotherapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: SABS) stock is to Strong Buy SABS stock.
Out of 2 analysts, 1 (50%) are recommending SABS as a Strong Buy, 1 (50%) are recommending SABS as a Buy, 0 (0%) are recommending SABS as a Hold, 0 (0%) are recommending SABS as a Sell, and 0 (0%) are recommending SABS as a Strong Sell.
What is SABS's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: SABS) forecast ROE is N/A, which is considered weak.
What is SABS's Price Target?
According to 2 Wall Street analysts that have issued a 1 year SABS price target, the average SABS price target is $3.50, with the highest SABS stock price forecast at $4.00 and the lowest SABS stock price forecast at $3.00.
On average, Wall Street analysts predict that Sab Biotherapeutics's share price could reach $3.50 by May 17, 2024. The average Sab Biotherapeutics stock price prediction forecasts a potential upside of 297.73% from the current SABS share price of $0.88.
What is SABS's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: SABS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.1%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.